编造重大虚假内容，上市首年虚增收入3000万！知名“减肥药概念股”及实控人等被罚7620万元

Core Viewpoint - ST诺泰 has faced administrative penalties from the China Securities Regulatory Commission (CSRC) and disciplinary actions from the Shanghai Stock Exchange due to significant violations, including fabricating major false content in public offering documents and inflating financial statements [1][3]. Group 1: Regulatory Actions - ST诺泰 received a total fine of 76.2 million yuan from the CSRC, with the company and its actual controller Zhao Dezhong among six individuals penalized [1]. - The CSRC found that ST诺泰's 2021 annual report contained false records, inflating operating income by 30 million yuan and total profit by 25.95 million yuan, which accounted for 20.64% of the reported total profit for that period [3]. - The Shanghai Stock Exchange issued a disciplinary decision against ST诺泰 and the responsible individuals, publicly reprimanding them and imposing restrictions on Zhao Dezhong's ability to serve as a director or submit listing applications for five years [7]. Group 2: Company Background - ST诺泰, established in 2009 and listed on the Sci-Tech Innovation Board in 2021, focuses on the research and development of peptide drugs and small molecule drugs [5]. - The company has been involved in the development of various pharmaceutical products, particularly in the peptide sector, and has a dual-driven development model combining self-selected and customized products [5]. Group 3: Financial Performance - In the first three quarters of 2025, ST诺泰 reported a revenue of 1.527 billion yuan, representing a year-on-year increase of 21.95%, and a net profit of 445 million yuan, up 26.92% [9]. - The company’s total operating income for 2025 was 1.527 billion yuan, with a gross profit margin reflecting a significant increase compared to previous years [10]. Group 4: Market Position and Developments - ST诺泰 was previously regarded as a promising stock in the weight-loss drug sector, particularly due to its involvement in the development of GLP-1 drugs [11]. - The company’s subsidiary, Hangzhou Nuoao Biopharmaceutical Technology Co., Ltd., has received approval for clinical trials of a new oral drug, Semaglutide, which is available in multiple dosages [11].